Welcome to Hyalgan Sites. This is your first post. Edit or delete it, then start writing!
Hyalgan for Healthcare ProfessionalsReferences
1. Data on file. Fidia Farmaceutici S.p.A., Italy. 2. Altman RD, Moskowitz R; HYALGAN® Study Group. Intraarticular sodium hyaluronate (HYALGAN®) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol. 1998;25(11):2203-2212. 3. Scali JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long term study. Eur J Rheumatol Inflamm. 1995;15(1):57-62. 4. Neustadt DH. Long-term efficacy and safety of intra-articular sodium hyaluronate (HYALGAN®) in patients with osteoarthritis of the knee. Clin Exp Rheumatol. 2003;21(3):307-311. 5. Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):253-263. 6. Miller LE, Block JE. An 8-week multimodal treatment program improves symptoms of knee osteoarthritis: a real-world multicenter experience. Pragmatic and Observational Research. 2013;4:39-44. 7. Miller LE, Block JE. An 8-week knee osteoarthritis treatment program of hyaluronic acid injection, deliberate physical rehabilitation, and patient education is cost effective at 2 years follow-up: The OsteoArthritis Centers of America™ Experience. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2014;7:49-55.
STUDY SUMMARY: ALTMAN, 1998
Intra-articular sodium hyaluronate (HYALGAN®) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial2
Study design
26-week, double-blind, placebo-controlled, multicenter study (N=495) in patients 40 years of age or older with K-L grade 2 or 3 OA of the knee, comparing IA HYALGAN® 20 mg weekly x 5 with IA saline and 500 mg bid naproxen. All patients were allowed up to 4000 mg/d for rescue analgesia (acetaminophen) as needed for pain
Results
- In the HYALGAN® pivotal trial (N=495), the 5-injection regimen significantly improved pain measures through 26 weeks of follow-up
- Patients receiving HYALGAN® experienced significantly less pain than those in the placebo group (P<.05) at Weeks 4, 5, 12, 21, and 26
- 2/3 of patients receiving HYALGAN® reported pain relief each month for 6 months
STUDY SUMMARY: SCALI, 1995
Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: A long-term study3
Study design
30-month, repeat-use, open-label study (N=75) of IA HYALGAN® 20mg weekly x5, repeated every 6 months for 5 treatment cycles. One cycle=5 injections. A total of 5 IA injections were administered
Results
- Progressive improvement in pain relief with repeat cycles over 30 months
- Improvements were observed after the first treatment cycle at 6 months and resulted in a 55% reduction in spontaneous pain at the end of the study (P<.001)
- No significant adverse events with repeat cycles
- Repeated treatment cycles improved symptoms, particularly in patients with early stage OA of the knee
- General assessment of overall treatment efficacy rated as “good” or “very good” with significant difference from baseline (P=.05) in 88% of patients
STUDY SUMMARY: NEUSTADT, 2003
Long-term efficacy and safety of intra-articular sodium hyaluronate (HYALGAN®) in patients with osteoarthritis of the knee4
Study design
Prospective cohort study to evaluate the long-term efficacy and safety of 5 weekly intra-articular injection of HYALGAN® in 76 patients (92 knees) with moderate to severe OA of the knee, whose pain was not controlled by conventional measures. Clinical improvement was defined as >50% reduction in a visual analog scale (VAS) for pain at rest, night pain, and pain on walking
Results
- Ten of 15 (67%) knees improved after a repeat treatment course
- 72% of patients achieved a greater than 50% improvement in VAS pain scores for 1 year or longer